Genzyme companies transfer cancer diagnostic IP (intellectual property):
This article was originally published in Clinica
Executive Summary
Genzyme Genetics has bought rights relating to IP and licences for cancer diagnostics from Genzyme Molecular Oncology for $32 million and up to $1 million in milestone payments. Both companies are business units of Cambridge, Massachusetts-based Genzyme General. Genzyme Genetics plans to use the acquired assets to develop and commercialise new specialised tests for a wide range of cancers. Genzyme Genetics also assumes exclusive rights to IP for cancer-related genes and diagnostic methods. As a result of this and other deals, Genzyme Molecular has around $40 million in cash, enough to fund operations into next year.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.